COPD-like airway inflammation during RSV infection of older volunteers: INFLAMMAGE

基于广泛的临床前和临床研究，我们假设RSV疾病代表了对感染的失调和过度活跃的炎症反应。目前尚无针对呼吸道合胞病毒疾病的特异性治疗方法，确定“可用药”的炎症途径将具有巨大的潜在临床价值。自然感染的观察性研究受到采样、时间和获取的限制。炎症的目的是研究在伦敦帝国理工学院使用实验性人类呼吸道合胞病毒感染的成年志愿者的炎症机制。这将使我们能够调查老年人非吸烟者和75岁以下吸烟者的呼吸道合胞病毒感染；使用体内和体外技术，我们将尝试定义新的临床终点，并发现预测结果的途径和生物标志物。这将使我们能够从GSK开发管道中的一系列有希望的药物中进行选择，这些药物可以抑制特定的炎症途径。下一阶段的研究将使我们能够预测GSK新型抗炎药治疗人类RSV疾病的可能影响，并发现慢性呼吸道疾病（包括COPD）病毒加重的新疗法。对疾病中潜在药物的测试将构成未来的最后阶段。

Based on extensive preclinical and clinical research we hypothesise that RSV disease represents a dysregulated and over-exuberant inflammatory response to infection. There is currently no specific treatment for RSV disease and identification of 'druggable' inflammatory pathways would be of great potential clinical value. Observational studies of natural infection are constrained by sampling, timing and access. The aim of INFLAMMAGE is to investigate the mechanisms of inflammation in adult volunteers using experimental human RSV infections at Imperial College London. This will enable us to investigate the RSV infection in older adult non-smokers and smokers up to 75 years of age; using in vivo and in vitro techniques, we will attempt to define novel clinical end-points and to discover pathways and biomarkers that predict outcome. This will allow us to select from a range of promising drugs in GSK's development pipeline that inhibit specific inflammatory pathways. This next phase of INFLAMMAGE will enable us to predict the possible impact of treatment with validated novel anti-inflammatory agents from GSK in human RSV disease and to discover new treatments for viral exacerbations of chronic respiratory disease, including COPD. The testing of potential drugs in disease will form the future final phase of INFLAMAGE.